Search Results
Oct 31, 2025, 04:00 ET Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration
VES001 had a favourable safety and tolerability profile during the three-month daily dosing regimen, with few adverse events (AEs) reported Results support progressing VES001 into Phase IIb/III trials in people with FTD-GRN, the variant of FTD caused by
More news about: Vesper Bio
Oct 27, 2025, 07:30 ET BTQ and ICTK Sign USD 15M Quantum-Secure Chip Development and Joint Investment Agreement to Advance Global Quantum-Safe Hardware
layer to enable crypto-agile upgrades without changing customer workflows. Early targets include up to 5× Advanced Encryption Standard (AES) throughput versus leading secure hardware, ~1 million digital signatures per second, and <1 microjoule per operation— defense and critical Infrastructure,
More news about: BTQ Technologies Corp.
Oct 24, 2025, 09:54 ET SK Life Science, Inc. to Host "Illuminating the Path to Added Seizure Reduction" Symposium at the 2025 American Epilepsy Society Annual Meeting
Biopharmaceuticals Co., Ltd., today announced it will host an educational symposium led by world-renowned epileptologists during the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia.
More news about: SK Life Science, Inc.
Oct 24, 2025, 05:49 ET HIKSEMI、Japan IT Week 秋展示会で注目を集め、インテリジェントストレージの新時代を披露
スマートモビリティ分野では、HIKSEMIのコンパクトUSBドライブとAEC-Q100認証済みeMMCが、過酷な条件下でも安定したインフォテインメントおよびADAS性能を保証し、コネクテッドカーやIoTデバイスの要求に応えます。 産業およびエンタープライズ向けには、HIKSEMIは高耐久性、低消費電力、AES-256暗号化を備えた耐久性の高い産業用ストレージおよびデータセンター向けSSDを提供しており、過酷な環境下でのAIトレーニング、クラウドコンピューティング、監視、オートメーションに最適です。 「データが流れるところ、生活が進化する」は、HIKSEMIの信念を表しており:データは単なるストレージではなく、知能、効率、そしてより豊かな体験を生み出す原動力であることを示しています。
More news about: Hiksemi
Oct 23, 2025, 09:00 ET Vivun Introduces Ava Assist: Unlocking Capacity for Every Sales Rep
rate. "At Gladly, we're embracing an AI-first selling approach, and Ava has been pivotal in accelerating sales cycles and empowering AEs with product knowledge," said Christian Eberle, Head of AI Solutions at Gladly. "It enables sellers to self-serve with technical and strategic
More news about: Vivun
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
signs of plateau. VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority of observed adverse events (AEs) being reported as mild or moderate. Treatment and study discontinuation rates among VK2735 cohorts were well-balanced compared with placebo.Following
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
weeks 4 and 12 (secondary endpoints). Incidence of fezolinetant-related treatment-emergent adverse events (AEs) in the study were low and consistent with clinical trials and post marketing data. No new safety signals were observed. Preliminary safety findings
More news about: Astellas Pharma Inc.
Oct 20, 2025, 17:00 ET PMET Resources Delivers Positive CV5 Lithium-Only Feasibility Study for its Large-Scale Shaakichiuwaanaan Project
Burnaby, BC, where the samples were homogenized and subsequently analysed for multi-element (including Li and Ta) using sodium peroxide fusion with ICP-AES/MS finish (codes GE_ICP91A50 and GE_IMS91A50).
More news about: PMET Resources Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
previously reported studies; with no new safety risks identified in the 12-week period.1,2,16 The most frequently reported treatment emergent AEs (≥ 3%) in any treatment group were urinary tract infection, nasopharyngitis and RA (worsening).1 Rates of serious adverse events were generally
More news about: AbbVie
Oct 20, 2025, 01:44 ET Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
(TEAEs) occurred in 69.8% of patients in trastuzumab botidotin and 63.7% in T-DM1. The most common TEAEs associated with dose reduction were ocular AEs for trastuzumab botidotin, and were platelet count decreased for trastuzumab emtansine. Only two patients permanently discontinued trastuzumab botidotin
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 20:10 ET ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
No Grade 4 or 5 treatment-related adverse event (TRAE) observed. Incidence of Grade ≥3 TRAEs, immune-related AEs (irAEs), and VEGF-related TRAEs was 13.9%, 4.2%, and 2.8%, respectively. Only 1 treatment-emergent adverse event (TEAE)
More news about: CStone Pharmaceuticals
Oct 19, 2025, 10:30 ET VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
escalation and dose expansion cohorts. The majority of reported adverse events (AEs) were categorized as mild or moderate in severity and the discontinuation rate due to AEs was low (3.5%). The most commonly reported treatment-related AEs were low grade fatigue, proteinuria (a reversible increase of protein in
More news about: Vivace Therapeutics, Inc.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
previously reported for this combination. The most common (≥30%) adverse events (AEs) reported in the neoadjuvant and adjuvant PADCEV plus KEYTRUDA arm were pruritus (itching), alopecia, diarrhea, fatigue and anemia. Grade ≥ 3 AEs due to any cause occurred in 71.3% of patients treated in the combination arm
More news about: Astellas Pharma Inc.
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
patients, with a similar pattern of adverse events (AEs) to that observed and reported in previously treated patients. Adverse events led to dose reductions in 11 patients (15%) and dose discontinuations in 7 patients (9%). The most commonly reported AEs were grade 1 diarrhea and rash.
More news about: Boehringer Ingelheim
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
PD-1-independent activity. The safety profile was consistent with selective T cell activation mechanism of action, and treatment-related AEs were transient and manageable with supportive care. Building on these clinical data, Marengo is advancing
More news about: Marengo Therapeutics
Oct 17, 2025, 02:54 ET Smart Data. Smarter Life: HIKSEMI Unveils AI-Powered Storage Innovations at GITEX 2025
For industrial and enterprise use, HIKSEMI leads with rugged storage cards and data center-grade SSDs. These feature high endurance, low power and AES-256 encryption. They are ideal for AI training, cloud computing, surveillance and industrial automation in harsh environments. "AI
More news about: Hiksemi
Oct 16, 2025, 10:00 ET Award-Winning Baseus Security X1 Pro: The World's First Smart AI Dual-Tracking Outdoor Security Camera, Now Crowdfunding on Kickstarter
No Cloud. No Subscription. Full Data Control: The X1 Pro outdoor dual camera keeps your data safe with AES + RSA dual encryption and EN 18031 privacy compliance while allowing you to store your data securely on local storage with no monthly subscription fees.
More news about: Baseus Technology (HK) Co., Ltd
Oct 16, 2025, 09:27 ET Abre Expands Advisory Council with New Esteemed Education Leaders
AES Advisory Group and former Superintendent of Hillsborough County Public Schools (FL), the seventh-largest district in the nation, with extensive
More news about: Abre
Oct 15, 2025, 04:15 ET UGREEN Makes Secure Local Storage Easy for Everyone with New DH Series NAS
Security is built into every layer. DH2300 ensures full control of personal data through local storage, protected by TLS/SSL, RSA, and AES encryption, two-factor authentication, and certifications from TÜV and TRUSTe. The built-in Security Manager adds 24/7 threat monitoring and scheduled
More news about: UGREEN Limited
Oct 15, 2025, 04:15 ET UGREEN macht mit dem neuesten NAS der DH-Serie sichere lokale Speicherung für jedermann einfach
Das DH2300 gewährleistet die vollständige Kontrolle über personenbezogene Daten durch lokale Speicherung, geschützt durch TLS/SSL-, RSA- und AES-Verschlüsselung, Zwei-Faktor-Authentifizierung sowie Zertifizierungen von TÜV und TRUSTe. Der integrierte Security Manager bietet eine umfassende Überwachung
More news about: UGREEN Limited
Oct 15, 2025, 04:15 ET UGREEN semplifica l'archiviazione locale sicura per tutti con il nuovo NAS della serie DH
integrata in ogni livello. DH2300 garantisce il pieno controllo dei dati personali tramite archiviazione locale, protetta da crittografia TLS/SSL, RSA e AES, autenticazione a due fattori e certificazioni TÜV e TRUSTe. Il Security Manager integrato aggiunge il monitoraggio delle minacce 24 ore su 24, 7 giorni
More news about: UGREEN Limited
Oct 15, 2025, 04:15 ET UGREEN facilita el almacenamiento local seguro para todos con la nueva serie NAS DH
todas las capas. El DH2300 garantiza el control total de los datos personales a través del almacenamiento local, protegido por cifrado TLS/SSL, RSA y AES, autenticación de dos factores y certificaciones de TÜV y TRUSTe. El administrador de seguridad integrado añade supervisión de amenazas las 24 horas
More news about: UGREEN Limited
Oct 15, 2025, 04:15 ET UGREEN simplifie le stockage local sécurisé pour tout le monde grâce à sa nouvelle série DH destinée au stockage en réseau (NAS)
intégrée à chaque couche. Le DH2300 assure un contrôle total des données personnelles grâce au stockage local, protégé par le chiffrement TLS/SSL, RSA et AES, l'authentification à deux facteurs ainsi que les certifications TÜV et TRUSTe. Le gestionnaire de sécurité intégré ajoute une surveillance permanente
More news about: UGREEN Limited
Oct 14, 2025, 14:55 ET Cambium Networks Introduces New Low-Cost, High-Performance Force 4518 and Force 4616 Subscriber Modules
Interoperable with ePMP 4500 series APs using MU-MIMO for sector-level efficiency Advanced QoS and 128-bit AES encryption (256-bit optional) Managed via
More news about: Cambium Networks
Oct 14, 2025, 06:18 ET Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
systemic AEs were generally mild for SCB-1022 and SCB-1033 and were comparable to SCB-1019, which had previously demonstrated significantly better tolerability than AREXVY in a separate trial. No vaccine related serious adverse events (SAEs), adverse events of special interest (AESIs), or AEs leading
More news about: Clover Biopharma